Literature DB >> 16822902

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.

Deepa Bhojwani1, Huining Kang, Naomi P Moskowitz, Dong-Joon Min, Hokyung Lee, Jeffrey W Potter, George Davidson, Cheryl L Willman, Michael J Borowitz, Ilana Belitskaya-Levy, Stephen P Hunger, Elizabeth A Raetz, William L Carroll.   

Abstract

Outcome for children with childhood acute lymphoblastic leukemia (ALL) who relapse is poor. To gain insight into the mechanisms of relapse, we analyzed gene-expression profiles in 35 matched diagnosis/relapse pairs as well as 60 uniformly treated children at relapse using the Affymetrix platform. Matched-pair analyses revealed significant differences in the expression of genes involved in cell-cycle regulation, DNA repair, and apoptosis between diagnostic and early-relapse samples. Many of these pathways have been implicated in tumorigenesis previously and are attractive targets for intervention strategies. In contrast, no common pattern of changes was observed among late-relapse pairs. Early-relapse samples were more likely to be similar to their respective diagnostic sample while we noted greater divergence in gene-expression patterns among late-relapse pairs. Comparison of expression profiles of early- versus late-relapse samples indicated that early-relapse clones were characterized by overexpression of biologic pathways associated with cell-cycle regulation. These results suggest that early-relapse results from the emergence of a related clone, characterized by the up-regulation of genes mediating cell proliferation. In contrast, late relapse appears to be mediated by diverse pathways.

Entities:  

Mesh:

Year:  2006        PMID: 16822902      PMCID: PMC1895482          DOI: 10.1182/blood-2006-02-002824

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  A gene expression map for Caenorhabditis elegans.

Authors:  S K Kim; J Lund; M Kiraly; K Duke; M Jiang; J M Stuart; A Eizinger; B N Wylie; G S Davidson
Journal:  Science       Date:  2001-09-14       Impact factor: 47.728

Review 3.  Validating survivin as a cancer therapeutic target.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

4.  Comparative analysis of multiple genome-scale data sets.

Authors:  Margaret Werner-Washburne; Brian Wylie; Kevin Boyack; Edwina Fuge; Judith Galbraith; Jose Weber; George Davidson
Journal:  Genome Res       Date:  2002-10       Impact factor: 9.043

5.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

6.  Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo.

Authors:  A Prokop; T Wieder; I Sturm; F Essmann; K Seeger; C Wuchter; W D Ludwig; G Henze; B Dörken; P T Daniel
Journal:  Leukemia       Date:  2000-09       Impact factor: 11.528

7.  Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.

Authors:  Rolf I Skotheim; Anne Kallioniemi; Bodil Bjerkhagen; Fredrik Mertens; Helge R Brekke; Outi Monni; Spyro Mousses; Nils Mandahl; Gunnar Soeter; Jahn M Nesland; Sigbjørn Smeland; Olli-P Kallioniemi; Ragnhild A Lothe
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma.

Authors:  S M Ansell; B K Arendt; D M Grote; D F Jelinek; A J Novak; L E Wellik; E D Remstein; C F Bennett; A Fielding
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

9.  Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia.

Authors:  Philipp Bernhard Staber; Werner Linkesch; Dorothea Zauner; Christine Beham-Schmid; Christian Guelly; Silvia Schauer; Heinz Sill; Gerald Hoefler
Journal:  Oncogene       Date:  2004-01-29       Impact factor: 9.867

10.  PTTG/securin activates expression of p53 and modulates its function.

Authors:  Tariq Hamid; Sham S Kakar
Journal:  Mol Cancer       Date:  2004-07-08       Impact factor: 27.401

View more
  61 in total

1.  Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.

Authors:  Shiuan Wey; Biquan Luo; Chun-Chih Tseng; Min Ni; Hui Zhou; Yong Fu; Deepa Bhojwani; William L Carroll; Amy S Lee
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.

Authors:  Johan Jansson; Yu-Chiao Hsu; Igor I Kuzin; Andrew Campbell; Craig A Mullen
Journal:  Leuk Res       Date:  2010-11-12       Impact factor: 3.156

3.  A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.

Authors:  S-H Chen; W Yang; Y Fan; G Stocco; K R Crews; J J Yang; S W Paugh; C-H Pui; W E Evans; M V Relling
Journal:  Leukemia       Date:  2010-11-12       Impact factor: 11.528

4.  Apoptosis pathway signature for prediction of treatment response and clinical outcome in childhood high risk B-Precursor acute lymphoblastic leukemia.

Authors:  Ya-Hsuan Chang; Yung-Li Yang; Chung-Ming Chen; Hsuan-Yu Chen
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

5.  Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.

Authors:  Laura E Hogan; Julia A Meyer; Jun Yang; Jinhua Wang; Nicholas Wong; Wenjian Yang; Gregory Condos; Stephen P Hunger; Elizabeth Raetz; Richard Saffery; Mary V Relling; Deepa Bhojwani; Debra J Morrison; William L Carroll
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

6.  Murine B-1 B cell progenitors initiate B-acute lymphoblastic leukemia with features of high-risk disease.

Authors:  Encarnacion Montecino-Rodriguez; Katy Li; Michael Fice; Kenneth Dorshkind
Journal:  J Immunol       Date:  2014-04-21       Impact factor: 5.422

Review 7.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 8.  Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

Authors:  Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

9.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

10.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.